Name:
MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)
Type:
Synthetic cannabinoid
AKA:
MDMB-FUBINACA (Positional Isomer: EMB-FUBINACA)
MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) image
Synthetic substance, no natural derivative
IUPAC Logo
MDMB-FUBINACA image
MDMB-FUBINACA, a synthetic cannabinoid, was first synthesized in the 2010s. It is known for its potent effects and was developed as part of a broader trend in synthetic cannabinoids. MDMB-FUBINACA's appearance in synthetic cannabis products has been associated with increased health risks, leading to regulatory scrutiny and control measures.
Synthetic Substances Image
MDMB-Fubinaca, a synthetic cannabinoid, is known for its potent psychoactive effects. As an upper, it causes intense euphoria and altered perception, with increased heart rate and dilated pupils. Short-term effects include anxiety and paranoia, while long-term use can lead to severe mental health issues and addiction. Overdose risks involve acute psychosis and cardiovascular problems. Safe use is challenging due to potency variability. Recent findings emphasize the need for regulation and caution due to high health risks and potential for severe adverse effects.
N/A
MDMB-Fubinaca, a synthetic cannabinoid, affects the endocannabinoid system, leading to altered mood and cognition. Psychological effects include euphoria, anxiety, and hallucinations. Effects last several hours, with risks of severe mental health issues and dependence. Research focuses on its safety profile and impact on mental health.
N/A
MDMB-Fubinaca is a synthetic cannabinoid with no historical or cultural lore, emerging in the early 21st century. Its cultural significance lies in its use as a legal high and the associated health and legal challenges. Proponents of synthetic cannabinoids highlight their effects and legal status in certain regions, while opponents warn of health risks and unpredictable effects. Its use is primarily recreational, reflecting broader issues in synthetic drug regulation and public health.
N/A